Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Pulmonary Sarcoidosis: early-phase trial registry

3 of 6 indexed Pulmonary Sarcoidosis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Pulmonary Sarcoidosis: 6 US clinical trials tracked, 3 recruiting.

Pulmonary Sarcoidosis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 2 of these trials.

Enrollment posture brief

Registry condition pulmonary-sarcoidosis

OPEN 3 | RECR 50% | LATE 1 | EARLY 3 | RANK #2866 | SPON 2

Nearest open-share peer: Achalasia (50% recruiting · 8 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Pulmonary Sarcoidosis (this)50%
Open-enrollment share among volume-matched conditions near Pulmonary Sarcoidosis

Pulmonary Sarcoidosis lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pulmonary Sarcoidosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pulmonary Sarcoidosis is recruiting above its size-band peers.

    3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Pulmonary Sarcoidosis research.

    National Heart, Lung, and Blood Institute (NHLBI) accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Pulmonary Sarcoidosis enrolment sits around 100 participants.

    Median target enrolment is 100 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. Pulmonary Sarcoidosis research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Pulmonary Sarcoidosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
N-acetyl-cysteine Dietary supplement
1 trials
Efzofitimod 5 mg/kg Drug
1 trials
Efzofitimod 3 mg/kg Drug
1 trials
OATD-01 Drug
1 trials
XTMAB-16 or Placebo Drug
1 trials
Pentoxifylline Drug
1 trials

US sites by state

Facility locations filed on Pulmonary Sarcoidosis trials. A trial with sites in several states counts in each.

Maryland 5 trials
Minnesota 3 trials
Colorado 3 trials
Alabama 3 trials
South Carolina 2 trials
Pennsylvania 2 trials
Ohio 2 trials
Michigan 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pulmonary Sarcoidosis page

6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pulmonary Sarcoidosis condition card totals 6 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.